← Back to Search

Monoclonal Antibodies

Lu AG09222 for Migraine

Phase 1
Waitlist Available
Research Sponsored by H. Lundbeck A/S
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial is testing a new drug called Lu AG09222, which is given as an injection under the skin. The study aims to understand how the body absorbs and eliminates this drug. Researchers will also check for any side effects or safety issues.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Side effects data

From 2023 Phase 2 trial • 237 Patients • NCT05133323
4%
Fatigue
4%
Covid-19
100%
80%
60%
40%
20%
0%
Study treatment Arm
Lu AG09222 Low Dose
Placebo
Lu AG09222 High Dose

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Lu AG09222 Low DoseExperimental Treatment1 Intervention
Participants will receive a single dose of Lu AG09222 by subcutaneous (SC) injection on Day 1.
Group II: Lu AG09222 High DoseExperimental Treatment1 Intervention
Participants will receive a single dose of Lu AG09222 by SC injection on Day 1.
Group III: PlaceboPlacebo Group1 Intervention
Participants will receive a single dose of placebo matching LU AG0922 by SC injection on Day 1.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lu AG09222
2022
Completed Phase 2
~350

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

H. Lundbeck A/SLead Sponsor
329 Previous Clinical Trials
77,618 Total Patients Enrolled
14 Trials studying Migraine
4,785 Patients Enrolled for Migraine
Email contact via H. Lundbeck A/SStudy DirectorH. Lundbeck A/S
189 Previous Clinical Trials
58,238 Total Patients Enrolled
12 Trials studying Migraine
4,185 Patients Enrolled for Migraine
~15 spots leftby Sep 2025